BCAB

BCAB

USD

BioAtla Inc. Common Stock

$0.673+0.023 (3.615%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.650

Kõrge

$0.678

Madal

$0.613

Maht

0.11M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

39.5M

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

1.01M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.24Praegune $0.673Kõrge $2.525

Seotud uudised

GlobeNewswire

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the

Vaata rohkem
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
GlobeNewswire

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its

Vaata rohkem
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025